VCIM
TRVI icon

Velan Capital Investment Management’s Trevi Therapeutics TRVI Stock Holding History

Velan Capital Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,500
Closed -$482K – 55
2025
Q4 		$482K Buy
+38,500
New +$445K 0.28% 27

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Velan Capital Investment Management's TRVI Position: Q1 2026 in Review

Velan Capital Investment Management sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 205,000 shares — an estimated $2.57M sold.

Velan Capital Investment Management first reported a position in TRVI in Q3 2025 and held it in 2 quarters. The position peaked at $2.57M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Velan Capital Investment Management reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Velan Capital Investment Management sold 205,000 Trevi Therapeutics shares in Q1 2026, an estimated $2.57M.
  • Velan Capital Investment Management first reported a position in Trevi Therapeutics in Q3 2025 and held it in 2 quarters.
  • Velan Capital Investment Management's Trevi Therapeutics position peaked at $2.57M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.